1 describe how they have re-examined the presumed cause of cyclosporine-associated cancers. It was previously held that such cancers result from a failure of the immune system to eliminate cancerous cells -presumably because, when treated with cyclosporine, the immune system cannot detect and respond to proteins associated specifically with the tumours. But Hojo and colleagues suggest a radically different explanation. They find that cyclosporine itself alters the characteristics of several cancerous cell lines in vitro and in vivo. The authors believe that it does this by inducing the synthesis of another molecule known as transforming growth factor-ȋ (TGF-ȋ).
Hojo et al. first found that, when exposed to cyclosporine in vitro, cancerous cells become more likely to divide, move and spread -they change shape, show increased mobility and, unlike normal cells, can grow without being anchored to a solid surface. Moreover, when the authors injected different types of tumour cells into immune-deficient mice, more secondary tumours developed in the lungs in the presence than in the absence of cyclosporine. These results challenge assumptions about how cyclosporineassociated tumours arise, and how immune surveillance is involved in the development of cancer. They also raise questions about how cyclosporine suppresses immune function, suggesting a more general role than previously thought for cyclosporine-dependent signalling pathways in human disease.
The mechanism of cyclosporine action has been described by several laboratories (reviewed in refs 2, 3). It was thought to block the immune system by inhibiting signalling through the T-cell receptor. The effect of this is to prevent the production of cytokines that would normally stimulate an immune response ( Fig. 1 ). But this explanation is not necessarily complete. First, when one of these cytokines, interleukin-2, is disrupted in transgenic animals, the effect on immune function is not the same as treatment with cyclosporine [4] [5] [6] [7] . Second, if another molecule in the proposed signalling pathway (the nuclear factor of activated T-cells, NF-AT) is knocked out, again the effects do not match treatment with cyclosporine 8 . An alternative explanation comes from the fact that cyclosporine stimulates the production of TGF-ȋ 9, 10 . We do not know how it does this, but it is an important avenue of further investigation because several previously mysterious side effects of cyclosporine can be explained by the induction of TGF-ȋ (Fig. 2) . For example, cyclosporine can cause liver damage, and thickening and scarring of the kidneys and skin -an effect also seen with increased TGF-ȋ 11 . Because TGF-ȋ is itself a well-known and potent immunosuppressive agent, increased production of TGF-ȋ -as wellas the inhibition of cytokine production -could explain the activity of cyclosporine.
Hojo et al. 1 have now recognized that, as well as affecting immune function, TGF-ȋ might alter the behaviour of cancerous cells. The remarkable changes that they observed in cyclosporine-treated cancerous cell lines were reversed when they added an antibody that bound to (and therefore blocked the action of) TGF-ȋ. In the same way, the increased spread of cancer cells in vivo was also blocked by the TGF-ȋ antibody. These results indicate that treatment with cyclosporine does not increase tumour growth indirectly, by a failure of the immune system, but rather directly through a nonimmune mechanism that acts on the tumour itself via TGF-ȋ receptors.
Hojo and colleagues' study is certainly provocative, calling into question the proposed mechanism by which cyclosporine induces secondary cancers. But several caveats should be noted. For example, we do not know whether cyclosporine has a similar effect on precancerous cells, or whether it is involved in converting cells from a benign to a cancerous state. Nonetheless, the data do indicate that cyclosporine and its relatives could exacerbate tumour growth in patients with existing tumours. Other studies point to a broader involvement of the signalling pathway triggered by cyclosporine in tissues outside the immune system. Molkentin, Olson and colleagues 12 , for example, have reported that increasing the expression of activated NF-AT3 in the heart muscle of transgenic mice leads to enlargement of the cardiac tissue (cardiac hypertrophy). Cardiac hypertrophy can be inhibited by giving mice cyclosporine 13 , although it is not clear whether TGF-ȋ is the mediator involved here. An alternative explanation may come from the finding that cyclosporine-mediated inhibition of calcineurin blocks the expression of muscle-specific genes, preventing hypertrophy 14 . Whatever the mechanism, these results indicate that a cyclosporine-like agent could be used to treat heart disease. However, such treatment would probably not be given unless the effects of cyclosporine on the immune system could somehow be reduced.
Hojo and colleagues' study will raise concerns about the increased incidence of cancer associated with cyclosporine treatment. This complication is, however, a well-known side effect of cyclosporine therapy, one that is currently balanced against the need to treat life-threatening diseases. The new observations do not alter this risk, nor do they sugused semi-inclusive deep-inelastic scattering of a positron beam to identify the contribution of individual quarks to the momentum of the proton. Both groups see an excess of virtual down-antiquarks over up-antiquarks, contradicting predictions that the two flavours of antiquark should be present inside the proton in equal numbers.
Elastic scattering is what happens with billiard balls -they collide and bounce without changing their identity and with no significant loss of kinetic energy. Inelastic scattering usually means that one or both of the colliding objects has been changed by the collision, in that they may be deformed or broken into pieces like a billiard ball shattered by a bullet. Deep-inelastic scattering is a subtle amalgam of the two, as if a bullet shatters a billiard ball but in the process makes a quasi-elastic collision with a heavy, compact ball-bearing buried inside the target. Particle physicists began to believe in the reality of quarks in the early 1970s (ref.
3), when deep-inelastic scattering experiments with electrons (bullets) on protons (billiard balls) gave far more large-angle electron scatters than expected. The results can be explained only if there are heavy, compact objects (the quarks, equivalent to the buried ball-bearings) inside the protons. This raises an obvious question: if an electron has a quasi-elastic scatter on a quark, should we not see the quark recoiling at a large angle too, leaving the shards of the proton behind? The answer is "Yes, but it is more complicated than that". What obscures the simple picture is a property of quarks that makes them harder to study than most other elementary particles, the fact that a single free quark can never be seen on its own. They are like the poles of a bar magnet -cut it in two and you don't get two free poles, you get two smaller magnets each with two poles. According to the successful theory of quantum chromodynamics (QCD), quarks are always surrounded by a local cloud of force-carrying particles called gluons, which act like the magnetic field around a magnetic pole. If we scatter an electron violently from a quark in a proton, then the quark begins to recoil like a free particle. But when it gets more than about 1 femtometre (10 ǁ15 m) from the remains of the proton, it stretches the gluon field sufficiently to allow a new quark-antiquark pair to be produced, and the antiquark sticks to the original quark and makes a meson.
In highly energetic collisions, many quark-antiquark pairs are created, producing a jet (Fig. 1) gest that any additional precautions be taken beyond those already recognized. But they do provide an insight into how these cancers come about, and may be useful in treating them. The results could also provide a lead in the search for new immunosuppressive drugs that might be more selective. But cyclosporine, whose mechanism of action was thought to be well understood, remains enigmatic in many respects.
S
ince the proton is the lightest stable composite object in the Universe we might expect it to be the simplest. Yet its structure is much more complicated than we can explain with current theories, as reported in Physical Review Letters by the HERMES collaboration 1 at the HERA accelerator in Hamburg and by the NuSea collaboration 2 at the Fermilab Tevatron near Chicago. HERMES 
